Imatron 1994 revenues rise by 34%

Article

Imatron, a manufacturer of ultra-high-speed CT systems, reported that sales jumped by 34% and the companyreturned to profitability in 1994 (ending Dec. 31). Revenues last year totaled a record $33.5 million, comparedto $25.1 million in 1993. Profits

Imatron, a manufacturer of ultra-high-speed CT systems, reported that sales jumped by 34% and the companyreturned to profitability in 1994 (ending Dec. 31).

Revenues last year totaled a record $33.5 million, comparedto $25.1 million in 1993. Profits were $2.3 million.

The financial good news is a continuation of positive trendsthat emerged in the second half of 1993, according to S. LewisMeyer, chief executive officer.

"The company moves into 1995 with a strong backlog anda high degree of optimism in our ability to continue growing,"he said.

Imatron is gearing up sales and marketing efforts in the PacificRim, Latin America and the Middle East. The launch of HeartScan,a subsidiary that will manage artery disease risk assessment centersequipped with Imatron high-speed CT scanners, is scheduled forthe first quarter of 1995, Meyer said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.